{"source_content":"请务必阅读最后一页股票评级说明和免责声明1医药生物报告原因：定期报告2020Q3血制品批签发数据跟踪维持评级Q3单季度出现下滑，Q1-Q3仍维持增长看好2020年11月5日行业研究/定期报告医药生物近一年市场表现季度批签发数据跟踪➢2020Q1-Q3国内累计批签发血制品7533万瓶，同比增长15.30%，其中Q1、Q2、Q3分别批签发2795.06万瓶、2548.36万瓶、2189.58万瓶，同比增长80.49%、14.44%、-20.61%。各品种批签发数据跟踪➢人血白蛋白：累计批签发4666.40万瓶，同比增长23.74%，其中Q1、Q2、Q3分别批签发1678.98万瓶、1615.19万瓶、1372.22万瓶，同比增长94.36%、15.97%、-9.41%；➢静注人免疫球蛋白（pH4）：累计批签发1055.21万瓶，同比增长11.28%，其中Q1、Q2、Q3分别批签发494.26万瓶、269.43万瓶、291.51万瓶，同比增长99.64%、4.26%、-34.08%；➢人免疫球蛋白：累计批签发124.89万瓶，同比增长118.46%，其中Q1、Q2、Q3分别批签发61.57万瓶、35.74万瓶、27.58万瓶，Q1、Q3同比增长153.77%、-16.19%；➢乙型肝炎人免疫球蛋白：累计批签发97.77万瓶，同比增长6.91%，其中Q1、Q2、Q3分别批签发27.40万瓶、32.34万瓶、38.03万瓶，同比增长159.87%、-49.09%、118.73%；➢破伤风人免疫球蛋白：累计批签发390.27万瓶，同比下降22.60%，其中Q1、Q2、Q3分别批签发162.08万瓶、143.14万瓶、85.06万瓶，同比增长23.93%、-3.19%、-62.29%；➢狂犬病人免疫球蛋白：累计批签发842.30万瓶，同比下降6.46%，其中Q1、Q2、Q3分别批签发247.07万瓶、331.97万瓶、263.26万瓶，同比增长27.42%、13.17%、-36.30%；➢人凝血因子VIII：累计批签发165.59万瓶，同比增长37.30%，其中Q1、Q2、Q3分别批签发60.16万瓶、40.75万瓶、64.69万瓶，同比增长63.43%、29.82%、23.43%；➢人凝血酶原复合物：PCC累计批签发108.84万瓶，同比增长49.54%，其中Q1、Q2、Q3分别批签发36.01万瓶、44.89万瓶、27.94万瓶，同比增长209.08%、85.89%、-24.45%；➢人纤维蛋白原：累计批签发81.72万瓶，同比增长21.63%，其中Q1、Q2、Q3分别批签发27.54万瓶、34.91万瓶、19.28万瓶，同比增长-5.90%、126.19%、-14.29%。分析师：刘建宏执业登记编码：S0760518030002电话：0351-8686724邮箱：liujianhong@sxzq.com太原市府西街69号国贸中心A座28层北京市西城区平安里西大街28号中海国际中心七层山西证券股份有限公司http://www.i618.com.cn证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明2上市公司批签发数据跟踪➢上海莱士：累计批签发血制品675.40万瓶，同比增长19.91%，其中Q1、Q2、Q3分别批签发269.83万瓶、176.26万瓶、229.31万瓶，同比增长113.36%、3.12%、-13.75%；➢华兰生物：累计批签发血制品557.27万瓶，同比下降3.62%，其中Q1、Q2、Q3分别批签发233.57万瓶、127.39万瓶、196.31万瓶，同比增长5.73%、-3.14%、-13.04%；➢天坛生物：累计批签发血制品805.03万瓶，同比增长2.48%，其中Q1、Q2、Q3分别批签发290.24万瓶、283.92万瓶、230.87万瓶，同比增长56.60%、-2.75%、-25.10%；➢卫光生物：累计批签发血制品283.27万瓶，同比增长20.39%，其中Q1、Q2、Q3分别批签发106.23万瓶、103.01万瓶、74.04万瓶，同比增长106%、38.24%、-32.21%；➢博雅生物：累计批签发血制品250.99万瓶，同比增长36.38%，其中Q1、Q2、Q3分别批签发107.74万瓶、78.05万瓶、65.20万瓶，同比增长168.84%、23.30%、-19.16%。➢双林生物：累计批签发血制品237.81万瓶，同比下降8.98%，其中Q1、Q2、Q3分别批签发80.25万瓶、73.29万瓶、84.27万瓶，同比增长17.04%、5.15%、-31.49%。投资建议➢2021Q1-Q3血制品整体及多数品种批签发维持增长。新冠疫情导致上半年国内采浆减少，下半年血制品供给紧张，Q3单季度血制品整体及多数品种批签发出现不同程度减少。疫情防控良好，国内采浆已从Q2逐步恢复，预计原料供应也将实现恢复。监管日益趋严，批签发集中头部龙头，行业集中度继续提升，我们维持长期看好观点，建议关注采浆能力强、生产规模大、产品丰富的优质血制品头部企业华兰生物、天坛生物等。风险提示：1）疫情变化风险；2）原料血浆供给不足风险；3）行业政策风险；4）产品安全风险；5）产品价格风险；6）研发与销售不达预期风险。证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明3目录1.季度批签发数据跟踪.......................................................................................................................................................71.1总批签发情况............................................................................................................................................................71.2各品种批签发情况....................................................................................................................................................82.各品种批签发数据跟踪.................................................................................................................................................82.1人血白蛋白................................................................................................................................................................82.2静注人免疫球蛋白（PH4）...................................................................................................................................102.3人免疫球蛋白...........................................................................................................................................................112.4乙型肝炎人免疫球蛋白...........................................................................................................................................112.5破伤风人免疫球蛋白..............................................................................................................................................122.6狂犬病人免疫球蛋白..............................................................................................................................................132.7人凝血因子VIII......................................................................................................................................................142.8人凝血酶原复合物..................................................................................................................................................152.9人纤维蛋白原..........................................................................................................................................................163.上市公司批签发数据跟踪.............................................................................................................................................173.1上海莱士..................................................................................................................................................................173.2华兰生物..................................................................................................................................................................183.3天坛生物..................................................................................................................................................................193.4卫光生物..................................................................................................................................................................203.5博雅生物..................................................................................................................................................................213.6双林生物..................................................................................................................................................................224.投资建议.........................................................................................................................................................................235.风险提示.........................................................................................................................................................................24证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明4图表目录图12011-2020Q1-Q3血制品批签发量（万瓶）及同比..................................................................................................7图22019年-2020年血制品月度批签发量（万瓶）.......................................................................................................7图32018Q1-2020Q3血制品批签发量（万瓶）................................................................................................................7图42020Q1-Q3各品种血制品批签发量（万瓶）..........................................................................................................8图52020Q1-Q3各品种血制品批签占比..........................................................................................................................8图72019年-2020年白蛋白月度批签发量（万瓶）......................................................................................................9图82018Q1-2020Q3白蛋白批签发量（万瓶）................................................................................................................9图92019与2020Q1-Q3国产、进口白蛋白批签发占比.........................................................................................................9图102019与2020Q1-Q3国产各生产企业白蛋白批签发占比................................................................................................9图112019年-2020年静丙月度批签发量（万瓶）................................................................................................................10图122011-2020Q1-Q3静丙批签发量（万瓶）及同比.................................................................................................10图132018Q1-2020Q3静丙批签发量（万瓶）..............................................................................................................10图142020Q1-Q3各企业静丙批签发占比......................................................................................................................10图152019年-2020年肌丙月度批签发量（万瓶）...............................................................................................................11图162011-2020Q1-Q3肌丙批签发量（万瓶）及同比..........................................................................................................11图172018Q1-2020Q3肌丙批签发量（万瓶）..............................................................................................................11图182020Q1-Q3各企业肌丙批签发占比......................................................................................................................11图192019年-2020年乙免月度批签发量（万瓶）...............................................................................................................12图202011-2020Q1-Q3乙免批签发量（万瓶）及同比..........................................................................................................12图212018Q1-2020Q3乙免批签发量（万瓶）..............................................................................................................12图222020Q1-Q3各企业乙免批签发占比......................................................................................................................12图232019年-2020年破免月度批签发量（万瓶）...............................................................................................................13图242011-2020Q1-Q3破免批签发量（万瓶）及同比..........................................................................................................13图252018Q1-2020Q3破免批签发量（万瓶）....................................................................................................................13图262020Q1-Q3各企业破免批签发占比......................................................................................................................13图272019年-2020年狂免月度批签发量（万瓶）...............................................................................................................14图282011-2020Q1-Q3狂免批签发量（万瓶）及同比.........................................................................................................14图292018Q1-2020Q3狂免批签发量（万瓶）....................................................................................................................14证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明5图302020Q1-Q3各企业狂免批签发占比......................................................................................................................14图312019年-2020年八因子月度批签发量（万瓶）............................................................................................................15图322011-2020Q1-Q3八因子批签发量（万瓶）及同比......................................................................................................15图332018Q1-2020Q3八因子批签发量（万瓶）.................................................................................................................15图342020Q1-Q3各企业八因子批签发占比..................................................................................................................15图352019年-2020年PCC月度批签发量（万瓶）..............................................................................................................16图362011-2020Q1-Q3PCC批签发量（万瓶）及同比.........................................................................................................16图372018Q1-2020Q3PCC批签发量（万瓶）....................................................................................................................16图382020Q1-Q3各企业PCC批签发占比....................................................................................................................16图392019年-2020年纤原月度批签发量（万瓶）...............................................................................................................17图402011-2020Q1-Q3纤原批签发量（万瓶）及同比..........................................................................................................17图412018Q1-2020Q3纤原批签发量（万瓶）....................................................................................................................17图422020Q1-Q3各企业纤原批签发占比......................................................................................................................17图432019年-2020年上海莱士血制品月度批签发量（万瓶）..............................................................................................18图442011-2020Q1-Q3上海莱士血制品批签发量（万瓶）及同比...............................................................................................18图452018Q1-2020Q3上海莱士血制品批签发量（万瓶）..............................................................................................18图462020H1上海莱士各品种血制品批签发量(万瓶).................................................................................................18图472019年-2020年华兰生物血制品月度批签发量（万瓶）..............................................................................................19图482011-2020Q1-Q3华兰生物血制品批签发量（万瓶）及同比...............................................................................................19图492018Q1-2020Q3华兰生物血制品批签发量（万瓶）....................................................................................................19图502020Q1-Q3华兰生物各品种血制品批签发量（万瓶）..................................................................................................19图512019年-2020年天坛生物血制品月度批签发量（万瓶）..............................................................................................20图522011-2020Q1-Q3天坛生物血制品批签发量（万瓶）及同比...............................................................................................20图532018Q1-2020Q3天坛生物血制品批签发量（万瓶）....................................................................................................20图542020Q1-Q3天坛生物各品种血制品批签发量（万瓶）..................................................................................................20图552019年-2020年卫光生物血制品月度批签发量（万瓶）..............................................................................................21图562011-2020Q1-Q3卫光生物血制品批签发量（万瓶）及同比...............................................................................................21图572018Q1-2020Q3卫光生物血制品批签发量（万瓶）....................................................................................................21图582020Q1-Q3卫光生物各品种血制品批签发量（万瓶）..................................................................................................21证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明6图592019年-2020年博雅生物血制品月度批签发量（万瓶）..............................................................................................22图602011-2020Q1-Q3博雅生物血制品批签发量（万瓶）及同比...............................................................................................22图612018Q1-2020Q3博雅生物血制品批签发量（万瓶）....................................................................................................22图622020Q1-Q3博雅生物各品种血制品批签发量（万瓶）..................................................................................................22图632019年-2020年双林生物血制品月度批签发量（万瓶）..............................................................................................23图642011-2020Q1-Q3双林生物血制品批签发量（万瓶）及同比...............................................................................................23图652018Q1-2020Q3双林生物血制品批签发量（万瓶）....................................................................................................23图662020Q1-Q3双林生物各品种血制品批签发量（万瓶）..................................................................................................23证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明71.季度批签发数据跟踪1.1总批签发情况2020Q1-Q3国内累计批签发血制品7533万瓶，同比增长15.30%，其中Q1、Q2、Q3分别批签发2795.06万瓶、2548.36万瓶、2189.58万瓶，同比增长80.49%、14.44%、-20.61%。图12011-2020Q1-Q3血制品批签发量（万瓶）及同比数据来源：Insight，山西证券研究所图22019年-2020年血制品月度批签发量（万瓶）图32018Q1-2020Q3血制品批签发量（万瓶）数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：所有产品均折算为标准规格。0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%0.001000.002000.003000.004000.005000.006000.007000.008000.002011Q1-Q32012Q1-Q32013Q1-Q32014Q1-Q32015Q1-Q32016Q1-Q32017Q1-Q32018Q1-Q32019Q1-Q32020Q1-Q30.00200.00400.00600.00800.001000.001200.001400.002019-012019-022019-032019-042019-052019-062019-072019-082019-092019-102019-112019-122020-012020-022020-032020-042020-052020-062020-072020-082020-090.00500.001000.001500.002000.002500.003000.00证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明81.2各品种批签发情况图42020Q1-Q3各品种血制品批签发量（万瓶）图52020Q1-Q3各品种血制品批签占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：➢人血白蛋白：简称白蛋白，统一折算为标准规格10g/瓶；➢静注人免疫球蛋白（pH4）：简称静丙，统一折算为标准规格2.5g/瓶；➢人免疫球蛋白：简称肌丙，统一折算为标准规格300mg/瓶；➢乙型肝炎人免疫球蛋白：简称乙免，统一折算为标准规格200IU/瓶；➢破伤风人免疫球蛋白：简称破免，统一折算为标准规格250IU/瓶；➢狂犬病人免疫球蛋白：简称狂免，统一折算为标准规格200IU/瓶；➢人凝血因子VIII：简称八因子，统一折算为标准规格200IU/瓶；➢人凝血酶原复合物：简称PCC，统一折算为标准规格200IU/瓶；➢人纤维蛋白原：简称纤原，统一折算为标准规格0.5g/瓶。2.各品种批签发数据跟踪2.1人血白蛋白2020Q1-Q3白蛋白累计批签发4666.40万瓶，同比增长23.74%，其中Q1、Q2、Q3分别批签发1678.98万瓶、1615.19万瓶、1372.22万瓶，同比增长94.36%、15.97%、-9.41%。Q1-Q3国产与进口白蛋白各批签发2221.46万瓶、2444.94万瓶，同比增长6.13%、45.70%，进口白蛋白占比同比提升7.89个百分点。从国产生产企业批签发情况来看，Q1-Q3天坛生物、泰邦生物、上海莱士、华兰生物各批签发395.78万瓶、291.544666.401055.21124.8997.77390.27842.30165.59108.8481.720.00500.001000.001500.002000.002500.003000.003500.004000.004500.005000.00白蛋白静丙肌丙乙免破免狂免八因子PCC纤原61.95%14.01%1.66%1.30%5.18%11.18%2.20%1.44%1.08%白蛋白静丙肌丙乙免破免狂免八因子PCC纤原证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明9万瓶、268.65万瓶、199.93万瓶，累计占比（国产白蛋白）52.03%。图62011-2020Q1-Q3白蛋白批签发量（万瓶）及同比数据来源：Insight，山西证券研究所图72019年-2020年白蛋白月度批签发量（万瓶）图82018Q1-2020Q3白蛋白批签发量（万瓶）数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图92019与2020Q1-Q3国产、进口白蛋白批签发占比图102019与2020Q1-Q3国产各生产企业白蛋白批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%0.00500.001000.001500.002000.002500.003000.003500.004000.004500.005000.002011Q1-Q32012Q1-Q32013Q1-Q32014Q1-Q32015Q1-Q32016Q1-Q32017Q1-Q32018Q1-Q32019Q1-Q32020Q1-Q30.00100.00200.00300.00400.00500.00600.00700.00800.002019-012019-022019-032019-042019-052019-062019-072019-082019-092019-102019-112019-122020-012020-022020-032020-042020-052020-062020-072020-082020-090.00200.00400.00600.00800.001000.001200.001400.001600.001800.0055.50%44.50%47.61%52.39%国产进口17.82%13.12%12.09%9.00%47.97%天坛生物泰邦生物上海莱士华兰生物其他证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明10注：人血白蛋白简称白蛋白，统一折算为标准规格10g/瓶。圆环图内圈为2019年，外圈为2020年。2.2静注人免疫球蛋白（pH4）2020Q1-Q3静丙累计批签发1055.21万瓶，同比增长11.28%，其中Q1、Q2、Q3分别批签发494.26万瓶、269.43万瓶、291.51万瓶，同比增长99.64%、4.26%、-34.08%。从生产企业批签发情况来看，Q1-Q3天坛生物批签发277.81万瓶，占比26.33%，位居首位；其次为上海莱士，批签发174.19万瓶，占比16.51%；另泰邦生物、华兰生物各批签发146.23万瓶、97.95万瓶。图112019年-2020年静丙月度批签发量（万瓶）图122011-2020Q1-Q3静丙批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图132018Q1-2020Q3静丙批签发量（万瓶）图142020Q1-Q3各企业静丙批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：静注人免疫球蛋白（pH4）简称静丙，统一折算为标准规格2.5g/瓶。0.0050.00100.00150.00200.00250.002019-012019-022019-032019-042019-052019-062019-072019-082019-092019-102019-112019-122020-012020-022020-032020-042020-052020-062020-072020-082020-09-10.00%0.00%10.00%20.00%30.00%40.00%50.00%60.00%0.00200.00400.00600.00800.001000.001200.000.00100.00200.00300.00400.00500.00600.0026.33%16.51%13.86%9.28%34.02%天坛生物上海莱士泰邦生物华兰生物其他证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明112.3人免疫球蛋白2020Q1-Q3肌丙累计批签发124.89万瓶，同比增长118.46%，其中Q1、Q2、Q3分别批签发61.57万瓶、35.74万瓶、27.58万瓶，Q1、Q3同比增长153.77%、-16.19%。从生产企业批签发情况来看，Q1-Q3博晖创新、德源生物各批签发35.25万瓶、27.77万瓶，分别占比28.22%、22.23%。图152019年-2020年肌丙月度批签发量（万瓶）图162011-2020Q1-Q3肌丙批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图172018Q1-2020Q3肌丙批签发量（万瓶）图182020Q1-Q3各企业肌丙批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：人免疫球蛋白简称肌丙，统一折算为标准规格300mg/瓶。2.4乙型肝炎人免疫球蛋白2020Q1-Q3乙免累计批签发97.77万瓶，同比增长6.91%，其中Q1、Q2、Q3分别批签发27.40万瓶、32.34万瓶、38.03万瓶，同比增长159.87%、-49.09%、118.73%。从生产企业批签发情况来看，Q1-Q3远大0.005.0010.0015.0020.0025.0030.0035.0040.0045.0050.002019-012019-022019-032019-042019-052019-062019-072019-082019-092019-102019-112019-122020-012020-022020-032020-042020-052020-062020-072020-082020-09-100.00%-50.00%0.00%50.00%100.00%150.00%200.00%250.00%300.00%350.00%400.00%0.0020.0040.0060.0080.00100.00120.00140.00160.000.0010.0020.0030.0040.0050.0060.0070.0080.0028.22%22.23%10.84%10.82%8.80%8.57%10.52%博晖创新德源生物卫光生物上海莱士派斯菲科博雅生物其他证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明12蜀阳累计批签发50.20万瓶，占比高达51.34%。图192019年-2020年乙免月度批签发量（万瓶）图202011-2020Q1-Q3乙免批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图212018Q1-2020Q3乙免批签发量（万瓶）图222020Q1-Q3各企业乙免批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：乙型肝炎人免疫球蛋白简称乙免，统一折算为标准规格200IU/瓶。2.5破伤风人免疫球蛋白2020Q1-Q3破免累计批签发390.27万瓶，同比下降22.60%，其中Q1、Q2、Q3分别批签发162.08万瓶、143.14万瓶、85.06万瓶，同比增长23.93%、-3.19%、-62.29%。从生产企业批签发情况来看，Q1-Q3泰邦生物批签发104.93万瓶，占比26.89%，华兰生物批签发85.52万瓶，占比21.91%。0.005.0010.0015.0020.0025.0030.0035.0040.002019-012019-022019-032019-042019-052019-062019-072019-082019-092019-102019-112019-122020-012020-022020-032020-042020-052020-062020-072020-082020-09-80.00%-60.00%-40.00%-20.00%0.00%20.00%40.00%60.00%0.0050.00100.00150.00200.00250.00300.000.0010.0020.0030.0040.0050.0060.0070.0051.34%19.66%11.38%7.64%9.98%远大蜀阳华兰生物天坛生物上海莱士其他证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明13图232019年-2020年破免月度批签发量（万瓶）图242011-2020Q1-Q3破免批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图252018Q1-2020Q3破免批签发量（万瓶）图262020Q1-Q3各企业破免批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：破伤风人免疫球蛋白简称破免，统一折算为标准规格250IU/瓶。2.6狂犬病人免疫球蛋白2020Q1-Q3狂免累计批签发842.30万瓶，同比下降6.46%，其中Q1、Q2、Q3分别批签发247.07万瓶、331.97万瓶、263.26万瓶，同比增长27.42%、13.17%、-36.30%。从生产企业批签发情况来看，Q1-Q3远大蜀阳、泰邦生物、卫光生物各批签发154.90万瓶、147.84万瓶、136.12万瓶，累计占比52.10%。0.0010.0020.0030.0040.0050.0060.0070.0080.0090.00100.002019-012019-022019-032019-042019-052019-062019-072019-082019-092019-102019-112019-122020-012020-022020-032020-042020-052020-062020-072020-082020-09-100.00%-50.00%0.00%50.00%100.00%150.00%0.00100.00200.00300.00400.00500.00600.000.0050.00100.00150.00200.00250.0026.89%21.91%15.39%13.06%11.89%9.17%1.69%泰邦生物华兰生物远大蜀阳天坛生物上海莱士双林生物其他证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明14图272019年-2020年狂免月度批签发量（万瓶）图282011-2020Q1-Q3狂免批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图292018Q1-2020Q3狂免批签发量（万瓶）图302020Q1-Q3各企业狂免批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：狂犬病人免疫球蛋白简称狂免，统一折算为标准规格200IU/瓶。2.7人凝血因子VIII2020Q1-Q3八因子累计批签发165.59万瓶，同比增长37.30%，其中Q1、Q2、Q3分别批签发60.16万瓶、40.75万瓶、64.69万瓶，同比增长63.43%、29.82%、23.43%。从生产企业批签发情况来看，Q1-Q3上海莱士批签发52.92万瓶，占比31.96%，位居首位，华兰生物、泰邦生物各批签发42.96万瓶、42.86万瓶，分别占比25.95%、25.89%。0.0020.0040.0060.0080.00100.00120.00140.00160.00180.002019-012019-022019-032019-042019-052019-062019-072019-082019-092019-102019-112019-122020-012020-022020-032020-042020-052020-062020-072020-082020-09-60.00%-40.00%-20.00%0.00%20.00%40.00%60.00%80.00%100.00%0.00100.00200.00300.00400.00500.00600.00700.00800.00900.001000.000.0050.00100.00150.00200.00250.00300.00350.00400.00450.0018.39%17.55%16.16%47.90%远大蜀阳泰邦生物卫光生物其他证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明15图312019年-2020年八因子月度批签发量（万瓶）图322011-2020Q1-Q3八因子批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图332018Q1-2020Q3八因子批签发量（万瓶）图342020Q1-Q3各企业八因子批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：人凝血因子VIII简称八因子，统一折算为标准规格200IU/瓶。2.8人凝血酶原复合物2020Q1-Q3PCC累计批签发108.84万瓶，同比增长49.54%，其中Q1、Q2、Q3分别批签发36.01万瓶、44.89万瓶、27.94万瓶，同比增长209.08%、85.89%、-24.45%。从生产企业批签发情况来看，Q1-Q3泰邦生物批签发64.74万瓶，占比高达59.48%；华兰生物批签发41万瓶，占比37.67%。0.005.0010.0015.0020.0025.0030.0035.002019-012019-022019-032019-042019-052019-062019-072019-082019-092019-102019-112019-122020-012020-022020-032020-042020-052020-062020-072020-082020-09-50.00%0.00%50.00%100.00%150.00%200.00%250.00%0.0020.0040.0060.0080.00100.00120.00140.00160.00180.000.0010.0020.0030.0040.0050.0060.0070.0031.96%25.95%25.89%15.99%0.22%上海莱士华兰生物泰邦生物绿十字天坛生物证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明16图352019年-2020年PCC月度批签发量（万瓶）图362011-2020Q1-Q3PCC批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图372018Q1-2020Q3PCC批签发量（万瓶）图382020Q1-Q3各企业PCC批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：人凝血酶原复合物简称PCC，统一折算为标准规格200IU/瓶。2.9人纤维蛋白原2020Q1-Q3纤维蛋白原累计批签发81.72万瓶，同比增长21.63%，其中Q1、Q2、Q3分别批签发27.54万瓶、34.91万瓶、19.28万瓶，同比增长-5.90%、126.19%、-14.29%。从生产企业批签发情况来看，Q1-Q3上海莱士批签发38.50万瓶，占比高达47.12%，泰邦生物、博雅生物各批签发21.05万瓶、12.92万瓶，分别占比25.75%、15.81%。0.005.0010.0015.0020.0025.0030.002019-012019-022019-032019-042019-052019-062019-072019-082019-092019-102019-112019-122020-012020-022020-032020-042020-052020-062020-072020-082020-09-40.00%-20.00%0.00%20.00%40.00%60.00%80.00%0.0020.0040.0060.0080.00100.00120.000.005.0010.0015.0020.0025.0030.0035.0040.0045.0050.0059.48%37.67%2.84%泰邦生物华兰生物南岳生物证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明17图392019年-2020年纤原月度批签发量（万瓶）图402011-2020Q1-Q3纤原批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图412018Q1-2020Q3纤原批签发量（万瓶）图422020Q1-Q3各企业纤原批签发占比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：人纤维蛋白原简称纤原，统一折算为标准规格0.5g/瓶。3.上市公司批签发数据跟踪3.1上海莱士2020Q1-Q3上海莱士累计批签发血制品675.40万瓶，同比增长19.91%，其中Q1、Q2、Q3分别批签发269.83万瓶、176.26万瓶、229.31万瓶，同比增长113.36%、3.12%、-13.75%。分品种来看，Q1-Q3白蛋白批签发268.65万瓶，同比增长18.01%；静丙批签发174.19万瓶，同比增长67.94%；肌丙批签发13.52万瓶，同比下降5.67%；乙免批签发7.47万瓶，同比下降62.51%；破免批签发46.39万瓶，同比增长17.09%；0.002.004.006.008.0010.0012.0014.0016.0018.002019-012019-022019-032019-042019-052019-062019-072019-082019-092019-102019-112019-122020-012020-022020-032020-042020-052020-062020-072020-082020-09-50.00%0.00%50.00%100.00%150.00%200.00%0.0010.0020.0030.0040.0050.0060.0070.0080.0090.00100.000.005.0010.0015.0020.0025.0030.0035.0040.0047.12%25.75%15.81%11.33%上海莱士泰邦生物博雅生物其他证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明18狂免批签发73.76万瓶，同比下降47.31%；八因子批签发52.92万瓶，同比增长235.36%；纤原批签发38.50万瓶，同比增长1611%。图432019年-2020年上海莱士血制品月度批签发量（万瓶）图442011-2020Q1-Q3上海莱士血制品批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图452018Q1-2020Q3上海莱士血制品批签发量（万瓶）图462020H1上海莱士各品种血制品批签发量(万瓶)数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：所有产品均折算为标准规格。3.2华兰生物2020Q1-Q3华兰生物累计批签发血制品557.27万瓶，同比下降3.62%，其中Q1、Q2、Q3分别批签发233.57万瓶、127.39万瓶、196.31万瓶，同比增长5.73%、-3.14%、-13.04%。分品种来看，Q1-Q3白蛋白批签发199.93万瓶，同比下降1.68%；静丙批签发97.95万瓶，同比下降26.45%；肌丙批签发6.25万瓶，同比下降40.52；乙免批签发19.23万瓶，同比增长73.59%；破免批签发85.52万瓶，同比增长0.57%；狂免批签发64.41万瓶，同比增长1.03%；八因子批签发42.96万瓶，同比下降2.45%；PCC批签发41.01万瓶，同比增长51.89%。0.0020.0040.0060.0080.00100.00120.00140.00160.002019-012019-022019-032019-042019-052019-062019-072019-082019-092019-102019-112019-122020-012020-022020-032020-042020-052020-062020-072020-082020-090.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%0.00100.00200.00300.00400.00500.00600.00700.00800.000.0050.00100.00150.00200.00250.00300.00268.65174.1913.527.4746.3973.7652.9238.500.0050.00100.00150.00200.00250.00300.00白蛋白静丙肌丙乙免破免狂免八因子纤原证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明19图472019年-2020年华兰生物血制品月度批签发量（万瓶）图482011-2020Q1-Q3华兰生物血制品批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图492018Q1-2020Q3华兰生物血制品批签发量（万瓶）图502020Q1-Q3华兰生物各品种血制品批签发量（万瓶）数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：所有产品均折算为标准规格。3.3天坛生物2020Q1-Q3天坛生物累计批签发血制品805.03万瓶，同比增长2.48%，其中Q1、Q2、Q3分别批签发290.24万瓶、283.92万瓶、230.87万瓶，同比增长56.60%、-2.75%、-25.10%。分品种来看，Q1-Q3白蛋白批签发395.78万瓶，同比增长16.45%；静丙批签发277.81万瓶，同比增长19.03%；肌丙批签发2.24万瓶，2019Q1-Q3无批签发；乙免批签发11.12万瓶，同比下降58.06%；破免批签发50.97万瓶，同比下降52.50%；狂免批签发66.74万瓶，同比下降14.95%；八因子批签发3673瓶，2019Q1-Q3无批签发。0.0020.0040.0060.0080.00100.00120.002019-012019-022019-032019-042019-052019-062019-072019-082019-092019-102019-112019-122020-012020-022020-032020-042020-052020-062020-072020-082020-09-40.00%-30.00%-20.00%-10.00%0.00%10.00%20.00%30.00%40.00%50.00%0.00100.00200.00300.00400.00500.00600.00700.000.0050.00100.00150.00200.00250.00300.00199.9397.956.2519.2385.5264.4142.9641.010.0050.00100.00150.00200.00250.00白蛋白静丙肌丙乙免破免狂免八因子PCC证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明20图512019年-2020年天坛生物血制品月度批签发量（万瓶）图522011-2020Q1-Q3天坛生物血制品批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图532018Q1-2020Q3天坛生物血制品批签发量（万瓶）图542020Q1-Q3天坛生物各品种血制品批签发量（万瓶）数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：所有产品均折算为标准规格。3.4卫光生物2020Q1-Q3卫光生物累计批签发血制品283.27万瓶，同比增长20.39%，其中Q1、Q2、Q3分别批签发106.23万瓶、103.01万瓶、74.04万瓶，同比增长106%、38.24%、-32.21%。分品种来看，Q1-Q3白蛋白批签发79.45万瓶，同比增长28.89%；静丙批签发48.48万瓶，同比增长8.78%；肌丙批签发13.53万瓶，同比增长4.02%；破免批签发4.62万瓶，同比下降78.12%；狂免批签发136.12万瓶，同比增长43.37%；纤原批签发1.07万瓶，2019年Q1-Q3无批签发。0.0020.0040.0060.0080.00100.00120.00140.002019-012019-022019-032019-042019-052019-062019-072019-082019-092019-102019-112019-122020-012020-022020-032020-042020-052020-062020-072020-082020-09-40.00%-20.00%0.00%20.00%40.00%60.00%80.00%100.00%120.00%140.00%0.00100.00200.00300.00400.00500.00600.00700.00800.00900.000.0050.00100.00150.00200.00250.00300.00350.00395.78277.812.2411.1250.9766.740.370.0050.00100.00150.00200.00250.00300.00350.00400.00450.00白蛋白静丙肌丙乙免破免狂免八因子证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明21图552019年-2020年卫光生物血制品月度批签发量（万瓶）图562011-2020Q1-Q3卫光生物血制品批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图572018Q1-2020Q3卫光生物血制品批签发量（万瓶）图582020Q1-Q3卫光生物各品种血制品批签发量（万瓶）数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：所有产品均折算为标准规格。3.5博雅生物2020Q1-Q3博雅生物累计批签发血制品250.99万瓶，同比增长36.38%，其中Q1、Q2、Q3分别批签发107.74万瓶、78.05万瓶、65.20万瓶，同比增长168.84%、23.30%、-19.16%。分品种来看，Q1-Q3白蛋白批签发113.52万瓶，同比增长83.86%；静丙批签发53.01万瓶，同比增长24.33%；肌丙批签发10.70万瓶，2019Q1-Q3无批签发；乙免批签发3.67万瓶，2019Q1-Q3无批签发；狂免批签发57.17万瓶，同比增长9.26%；纤原批签发12.92万瓶，同比下降52.73%。0.0010.0020.0030.0040.0050.0060.0070.002019-012019-022019-032019-042019-052019-062019-072019-082019-092019-102019-112019-122020-012020-022020-032020-042020-052020-062020-072020-082020-09-50.00%0.00%50.00%100.00%150.00%200.00%250.00%0.0050.00100.00150.00200.00250.00300.000.0020.0040.0060.0080.00100.00120.0079.4548.4813.534.62136.121.070.0020.0040.0060.0080.00100.00120.00140.00160.00白蛋白静丙肌丙破免狂免纤原证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明22图592019年-2020年博雅生物血制品月度批签发量（万瓶）图602011-2020Q1-Q3博雅生物血制品批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图612018Q1-2020Q3博雅生物血制品批签发量（万瓶）图622020Q1-Q3博雅生物各品种血制品批签发量（万瓶）数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：所有产品均折算为标准规格。3.6双林生物2020Q1-Q3双林生物累计批签发血制品237.81万瓶，同比下降8.98%，其中Q1、Q2、Q3分别批签发80.25万瓶、73.29万瓶、84.27万瓶，同比增长17.04%、5.15%、-31.49%。分品种来看，Q1-Q3白蛋白批签发64.39万瓶，同比下降14.77%；静丙批签发47.34万瓶，同比增长21.86%；破免批签发35.79万瓶，同比增长0.27%%;狂免批签发90.30万瓶，同比下降18.78%。0.0010.0020.0030.0040.0050.0060.002019-012019-022019-032019-042019-052019-062019-072019-082019-092019-102019-112019-122020-012020-022020-032020-042020-052020-062020-072020-082020-09-20.00%0.00%20.00%40.00%60.00%80.00%100.00%120.00%140.00%0.0050.00100.00150.00200.00250.00300.000.0020.0040.0060.0080.00100.00120.00113.5253.0110.703.6757.1712.920.0020.0040.0060.0080.00100.00120.00白蛋白静丙肌丙乙免狂免纤原证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明23图632019年-2020年双林生物血制品月度批签发量（万瓶）图642011-2020Q1-Q3双林生物血制品批签发量（万瓶）及同比数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所图652018Q1-2020Q3双林生物血制品批签发量（万瓶）图662020Q1-Q3双林生物各品种血制品批签发量（万瓶）数据来源：Insight，山西证券研究所数据来源：Insight，山西证券研究所注：所有产品均折算为标准规格。4.投资建议2021Q1-Q3血制品整体及多数品种批签发维持增长。新冠疫情导致上半年国内采浆减少，下半年血制品供给紧张，Q3单季度血制品整体及多数品种批签发出现不同程度减少。疫情防控良好，国内采浆已从Q2逐步恢复，预计原料供应也将实现恢复。监管日益趋严，批签发集中头部龙头，行业集中度继续提升，我们维持长期看好观点，建议关注采浆能力强、生产规模大、产品丰富的优质血制品头部企业华兰生物、天坛生物等。0.0010.0020.0030.0040.0050.0060.0070.002019-012019-022019-032019-042019-052019-062019-072019-082019-092019-102019-112019-122020-012020-022020-032020-042020-052020-062020-072020-082020-09-40.00%-20.00%0.00%20.00%40.00%60.00%80.00%0.0050.00100.00150.00200.00250.00300.000.0020.0040.0060.0080.00100.00120.00140.0064.3947.3435.7990.300.0010.0020.0030.0040.0050.0060.0070.0080.0090.00100.00白蛋白静丙破免狂免证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明245.风险提示1）疫情变化风险；2）原料血浆供给不足风险；3）行业政策风险；4）产品安全风险；5）产品价格风险；6）研发与销售不达预期风险。证券研究报告：行业研究/定期报告请务必阅读最后一页股票评级说明和免责声明25分析师承诺：本人具有中国证券业协会授予的证券投资咨询执业资格并注册为证券分析师，本人承诺，以勤勉的职业态度，独立、客观地出具本报告。本报告清晰准确地反映本人的研究观点。本人不曾因，不因，也将不会因本报告中的具体推荐意见或观点而直接或间接受到任何形式的补偿。本人承诺不利用自己的身份、地位和执业过程中所掌握的信息为自己或他人谋取私利。投资评级的说明：——报告发布后的6个月内上市公司股票涨跌幅相对同期上证指数/深证成指的涨跌幅为基准——股票投资评级标准：买入：相对强于市场表现20%以上增持：相对强于市场表现5～20%中性：相对市场表现在-5%～+5%之间波动减持：相对弱于市场表现5%以下——行业投资评级标准：看好：行业超越市场整体表现中性：行业与整体市场表现基本持平看淡：行业弱于整体市场表现免责声明：山西证券股份有限公司(以下简称“本公司”)具备证券投资咨询业务资格。本报告是基于本公司认为可靠的已公开信息，但本公司不保证该等信息的准确性或完整性。入市有风险，投资需谨慎。在任何情况下，本报告中的信息或所表述的意见并不构成对任何人的投资建议。在任何情况下，本公司不对任何人因使用本报告中的任何内容所引致的任何损失负任何责任。本报告所载的资料、意见及推测仅反映本所于发布本报告当日的判断。在不同时期，本所可发出与本报告所载资料、意见及推测不一致的报告。本公司或其关联机构在法律许可的情况下可能持有或交易本报告中提到的上市公司所发行的证券或投资标的，还可能为或争取为这些公司提供投资银行或财务顾问服务。客户应当考虑到本公司可能存在可能影响本报告客观性的利益冲突。本公司在知晓范围内履行披露义务。本报告的版权归本公司所有。本公司对本报告保留一切权利。未经本公司事先书面授权，本报告的任何部分均不得以任何方式制作任何形式的拷贝、复印件或复制品，或再次分发给任何其他人，或以任何侵犯本公司版权的其他方式使用。否则，本公司将保留随时追究其法律责任的权利。依据《发布证券研究报告执业规范》规定特此声明，禁止我司员工将我司证券研究报告私自提供给未经我司授权的任何公众媒体或者其他机构；禁止任何公众媒体或者其他机构未经授权私自刊载或者转发我司的证券研究报告。刊载或者转发我司证券研究报告的授权必须通过签署协议约定，且明确由被授权机构承担相关刊载或者转发责任。依据《发布证券研究报告执业规范》规定特此提示我司证券研究业务客户不要将我司证券研究报告转发给他人，提示我司证券研究业务客户及公众投资者慎重使用公众媒体刊载的证券研究报告。依据《证券期货经营机构及其工作人员廉洁从业规定》和《证券经营机构及其工作人员廉洁从业实施细则》规定特此告知我司证券研究业务客户遵守廉洁从业规定。山西证券研究所：太原北京太原市府西街69号国贸中心A座28层电话：0351-8686981http://www.i618.com.cn北京市西城区平安里西大街28号中海国际中心七层电话：010-83496336","data":[{"id":"1","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"2020Q1-Q3国内累计批签发血制品7533万瓶，","content_offset":["116","142"],"indicators":[{"indicator_name":"批签发量","indicator_value":["7533万瓶","135","141"],"indicator_element":{"时间":["2020Q1-Q3","116","125"],"区域":["国内","125","127"],"行业":["血制品","132","135"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长15.30%","content_offset":["142","152"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["15.30%","146","152"],"indicator_element":{"时间":["2020Q1-Q3","116","125"],"区域":["国内","125","127"],"行业":["血制品","132","135"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"其中Q1、Q2、Q3分别批签发2795.06万瓶、2548.36万瓶、2189.58万瓶","content_offset":["153","197"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2795.06万瓶","168","177"],"indicator_element":{"时间":["2020","76","80"],"区域":["国内","125","127"],"行业":["血制品","132","135"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["2548.36万瓶","178","187"],"indicator_element":{"时间":["2020","76","80"],"区域":["国内","125","127"],"行业":["血制品","132","135"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["2189.58万瓶","188","197"],"indicator_element":{"时间":["2020","76","80"],"区域":["国内","125","127"],"行业":["血制品","132","135"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长80.49%、14.44%、-20.61%","content_offset":["198","223"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["80.49%","202","208"],"indicator_element":{"时间":["2020","116","120"],"区域":["国内","125","127"],"行业":["血制品","132","135"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["14.44%","209","215"],"indicator_element":{"时间":["2020","116","120"],"区域":["国内","125","127"],"行业":["血制品","132","135"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-20.61%","216","223"],"indicator_element":{"时间":["2020","116","120"],"区域":["国内","125","127"],"行业":["血制品","132","135"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"累计批签发4666.40万瓶，","content_offset":["241","256"],"indicators":[{"indicator_name":"批签发量","indicator_value":["4666.40万瓶","246","255"],"indicator_element":{"产品":["人血白蛋白","235","240"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长23.74%","content_offset":["256","266"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["23.74%","260","266"],"indicator_element":{"产品":["人血白蛋白","235","240"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"其中Q1、Q2、Q3分别批签发1678.98万瓶、1615.19万瓶、1372.22万瓶","content_offset":["267","311"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1678.98万瓶","282","291"],"indicator_element":{"时间":["Q1","269","271"],"产品":["人血白蛋白","235","240"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["1615.19万瓶","292","301"],"indicator_element":{"时间":["Q2","272","274"],"产品":["人血白蛋白","235","240"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["1372.22万瓶","302","311"],"indicator_element":{"时间":["Q3","275","277"],"产品":["人血白蛋白","235","240"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长94.36%、15.97%、-9.41%","content_offset":["312","336"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["94.36%","316","322"],"indicator_element":{"时间":["Q1","269","271"],"产品":["人血白蛋白","235","240"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["15.97%","323","329"],"indicator_element":{"时间":["Q2","272","274"],"产品":["人血白蛋白","235","240"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-9.41%","330","336"],"indicator_element":{"时间":["Q3","275","277"],"产品":["人血白蛋白","235","240"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"累计批签发1055.21万瓶，","content_offset":["352","367"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1055.21万瓶","357","366"],"indicator_element":{"产品":["静注人免疫球蛋白","338","346"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长11.28%","content_offset":["367","377"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["11.28%","371","377"],"indicator_element":{"产品":["静注人免疫球蛋白","338","346"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"其中Q1、Q2、Q3分别批签发494.26万瓶、269.43万瓶、291.51万瓶","content_offset":["378","419"],"indicators":[{"indicator_name":"批签发量","indicator_value":["494.26万瓶","393","401"],"indicator_element":{"时间":["Q1","380","382"],"产品":["静注人免疫球蛋白","338","346"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["269.43万瓶","402","410"],"indicator_element":{"时间":["Q2","383","385"],"产品":["静注人免疫球蛋白","338","346"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["291.51万瓶","411","419"],"indicator_element":{"时间":["Q3","386","388"],"产品":["静注人免疫球蛋白","338","346"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长99.64%、4.26%、-34.08%","content_offset":["420","444"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["99.64%","424","430"],"indicator_element":{"时间":["Q1","380","382"],"产品":["静注人免疫球蛋白","338","346"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["4.26%","431","436"],"indicator_element":{"时间":["Q2","383","385"],"产品":["静注人免疫球蛋白","338","346"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-34.08%","437","444"],"indicator_element":{"时间":["Q3","386","388"],"产品":["静注人免疫球蛋白","338","346"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"累计批签发124.89万瓶，","content_offset":["453","467"],"indicators":[{"indicator_name":"批签发量","indicator_value":["124.89万瓶","458","466"],"indicator_element":{"产品":["人免疫球蛋白","446","452"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长118.46%","content_offset":["467","478"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["118.46%","471","478"],"indicator_element":{"产品":["人免疫球蛋白","446","452"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"其中Q1、Q2、Q3分别批签发61.57万瓶、35.74万瓶、27.58万瓶","content_offset":["479","517"],"indicators":[{"indicator_name":"批签发量","indicator_value":["61.57万瓶","494","501"],"indicator_element":{"时间":["Q1","481","483"],"产品":["人免疫球蛋白","446","452"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["35.74万瓶","502","509"],"indicator_element":{"时间":["Q2","484","486"],"产品":["人免疫球蛋白","446","452"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["27.58万瓶","510","517"],"indicator_element":{"时间":["Q3","487","489"],"产品":["人免疫球蛋白","446","452"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"Q1、Q3同比增长153.77%、-16.19%","content_offset":["518","542"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["153.77%","527","534"],"indicator_element":{"时间":["Q1","518","520"],"产品":["人免疫球蛋白","446","452"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-16.19%","535","542"],"indicator_element":{"时间":["Q3","521","523"],"产品":["人免疫球蛋白","446","452"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["","518","518"],"indicator_element":{"产品":["人免疫球蛋白","446","452"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长6.91%","content_offset":["568","577"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["6.91%","572","577"],"indicator_element":{"产品":["乙型肝炎人免疫球蛋白","544","554"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"其中Q1、Q2、Q3分别批签发27.40万瓶、32.34万瓶、38.03万瓶","content_offset":["578","616"],"indicators":[{"indicator_name":"批签发量","indicator_value":["27.40万瓶","593","600"],"indicator_element":{"时间":["Q1","580","582"],"产品":["乙型肝炎人免疫球蛋白","544","554"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["32.34万瓶","601","608"],"indicator_element":{"时间":["Q2","583","585"],"产品":["乙型肝炎人免疫球蛋白","544","554"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["38.03万瓶","609","616"],"indicator_element":{"时间":["Q3","586","588"],"产品":["乙型肝炎人免疫球蛋白","544","554"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长159.87%、-49.09%、118.73%","content_offset":["617","644"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["159.87%","621","628"],"indicator_element":{"时间":["Q1","518","520"],"产品":["乙型肝炎人免疫球蛋白","544","554"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-49.09%","629","636"],"indicator_element":{"时间":["Q2","583","585"],"产品":["乙型肝炎人免疫球蛋白","544","554"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["118.73%","637","644"],"indicator_element":{"时间":["Q3","521","523"],"产品":["乙型肝炎人免疫球蛋白","544","554"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"累计批签发390.27万瓶，","content_offset":["656","670"],"indicators":[{"indicator_name":"批签发量","indicator_value":["390.27万瓶","661","669"],"indicator_element":{"产品":["破伤风人免疫球蛋白","646","655"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比下降22.60%","content_offset":["670","680"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["22.60%","674","680"],"indicator_element":{"产品":["破伤风人免疫球蛋白","646","655"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"其中Q1、Q2、Q3分别批签发162.08万瓶、143.14万瓶、85.06万瓶","content_offset":["681","721"],"indicators":[{"indicator_name":"批签发量","indicator_value":["162.08万瓶","696","704"],"indicator_element":{"时间":["Q1","683","685"],"产品":["破伤风人免疫球蛋白","646","655"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["143.14万瓶","705","713"],"indicator_element":{"时间":["Q2","686","688"],"产品":["破伤风人免疫球蛋白","646","655"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["85.06万瓶","714","721"],"indicator_element":{"时间":["Q3","689","691"],"产品":["破伤风人免疫球蛋白","646","655"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长23.93%、-3.19%、-62.29%","content_offset":["722","747"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["23.93%","726","732"],"indicator_element":{"时间":["Q1","683","685"],"产品":["破伤风人免疫球蛋白","646","655"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-3.19%","733","739"],"indicator_element":{"时间":["Q2","686","688"],"产品":["破伤风人免疫球蛋白","646","655"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-62.29%","740","747"],"indicator_element":{"时间":["Q3","689","691"],"产品":["破伤风人免疫球蛋白","646","655"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"累计批签发842.30万瓶，","content_offset":["759","773"],"indicators":[{"indicator_name":"批签发量","indicator_value":["842.30万瓶","764","772"],"indicator_element":{"产品":["狂犬病人免疫球蛋白","749","758"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比下降6.46%","content_offset":["773","782"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["6.46%","777","782"],"indicator_element":{"产品":["狂犬病人免疫球蛋白","749","758"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"其中Q1、Q2、Q3分别批签发247.07万瓶、331.97万瓶、263.26万瓶","content_offset":["783","824"],"indicators":[{"indicator_name":"批签发量","indicator_value":["247.07万瓶","798","806"],"indicator_element":{"时间":["Q1","785","787"],"产品":["狂犬病人免疫球蛋白","749","758"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["331.97万瓶","807","815"],"indicator_element":{"时间":["Q2","788","790"],"产品":["狂犬病人免疫球蛋白","749","758"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["263.26万瓶","816","824"],"indicator_element":{"时间":["Q3","791","793"],"产品":["狂犬病人免疫球蛋白","749","758"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长27.42%、13.17%、-36.30%","content_offset":["825","850"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["27.42%","829","835"],"indicator_element":{"时间":["Q1","785","787"],"产品":["狂犬病人免疫球蛋白","749","758"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["13.17%","836","842"],"indicator_element":{"时间":["Q2","788","790"],"产品":["狂犬病人免疫球蛋白","749","758"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-36.30%","843","850"],"indicator_element":{"时间":["Q3","791","793"],"产品":["狂犬病人免疫球蛋白","749","758"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"累计批签发165.59万瓶，","content_offset":["862","876"],"indicators":[{"indicator_name":"批签发量","indicator_value":["165.59万瓶","867","875"],"indicator_element":{"产品":["人凝血因子VIII","852","861"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长37.30%","content_offset":["876","886"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["37.30%","880","886"],"indicator_element":{"产品":["人凝血因子VIII","852","861"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"其中Q1、Q2、Q3分别批签发60.16万瓶、40.75万瓶、64.69万瓶","content_offset":["887","925"],"indicators":[{"indicator_name":"批签发量","indicator_value":["60.16万瓶","902","909"],"indicator_element":{"时间":["Q1","889","891"],"产品":["人凝血因子VIII","852","861"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["40.75万瓶","910","917"],"indicator_element":{"时间":["Q2","892","894"],"产品":["人凝血因子VIII","852","861"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["64.69万瓶","918","925"],"indicator_element":{"时间":["Q3","895","897"],"产品":["人凝血因子VIII","852","861"]},"indicator_supplement":{"属性":""}}]},{"id":"32","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长63.43%、29.82%、23.43%","content_offset":["926","950"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["63.43%","930","936"],"indicator_element":{"时间":["Q1","889","891"],"产品":["人凝血因子VIII","852","861"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["29.82%","937","943"],"indicator_element":{"时间":["Q2","892","894"],"产品":["人凝血因子VIII","852","861"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["23.43%","944","950"],"indicator_element":{"时间":["Q3","895","897"],"产品":["人凝血因子VIII","852","861"]},"indicator_supplement":{"属性":""}}]},{"id":"33","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"PCC累计批签发108.84万瓶，","content_offset":["961","978"],"indicators":[{"indicator_name":"批签发量","indicator_value":["108.84万瓶","969","977"],"indicator_element":{"产品":["人凝血酶原复合物","952","960"]},"indicator_supplement":{"属性":""}}]},{"id":"34","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长49.54%","content_offset":["978","988"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["49.54%","982","988"],"indicator_element":{"产品":["人凝血酶原复合物","952","960"]},"indicator_supplement":{"属性":""}}]},{"id":"35","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"其中Q1、Q2、Q3分别批签发36.01万瓶、44.89万瓶、27.94万瓶","content_offset":["989","1027"],"indicators":[{"indicator_name":"批签发量","indicator_value":["36.01万瓶","1004","1011"],"indicator_element":{"时间":["Q1","991","993"],"产品":["人凝血酶原复合物","952","960"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["44.89万瓶","1012","1019"],"indicator_element":{"时间":["Q2","994","996"],"产品":["人凝血酶原复合物","952","960"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["27.94万瓶","1020","1027"],"indicator_element":{"时间":["Q3","997","999"],"产品":["人凝血酶原复合物","952","960"]},"indicator_supplement":{"属性":""}}]},{"id":"36","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长209.08%、85.89%、-24.45%","content_offset":["1028","1054"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["209.08%","1032","1039"],"indicator_element":{"时间":["Q1","991","993"],"产品":["人凝血酶原复合物","952","960"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["85.89%","1040","1046"],"indicator_element":{"时间":["Q2","994","996"],"产品":["人凝血酶原复合物","952","960"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-24.45%","1047","1054"],"indicator_element":{"时间":["Q3","997","999"],"产品":["人凝血酶原复合物","952","960"]},"indicator_supplement":{"属性":""}}]},{"id":"37","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"累计批签发81.72万瓶，","content_offset":["1063","1076"],"indicators":[{"indicator_name":"批签发量","indicator_value":["81.72万瓶","1068","1075"],"indicator_element":{"产品":["人纤维蛋白原","1056","1062"]},"indicator_supplement":{"属性":""}}]},{"id":"38","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长21.63%","content_offset":["1076","1086"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["21.63%","1080","1086"],"indicator_element":{"产品":["人纤维蛋白原","1056","1062"]},"indicator_supplement":{"属性":""}}]},{"id":"39","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"其中Q1、Q2、Q3分别批签发27.54万瓶、34.91万瓶、19.28万瓶","content_offset":["1087","1125"],"indicators":[{"indicator_name":"批签发量","indicator_value":["27.54万瓶","1102","1109"],"indicator_element":{"时间":["Q1","1089","1091"],"产品":["人纤维蛋白原","1056","1062"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["34.91万瓶","1110","1117"],"indicator_element":{"时间":["Q2","1092","1094"],"产品":["人纤维蛋白原","1056","1062"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["19.28万瓶","1118","1125"],"indicator_element":{"时间":["Q3","1095","1097"],"产品":["人纤维蛋白原","1056","1062"]},"indicator_supplement":{"属性":""}}]},{"id":"40","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长-5.90%、126.19%、-14.29%","content_offset":["1126","1152"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-5.90%","1130","1136"],"indicator_element":{"时间":["Q1","1089","1091"],"产品":["人纤维蛋白原","1056","1062"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["126.19%","1137","1144"],"indicator_element":{"时间":["Q2","1092","1094"],"产品":["人纤维蛋白原","1056","1062"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-14.29%","1145","1152"],"indicator_element":{"时间":["Q3","1095","1097"],"产品":["人纤维蛋白原","1056","1062"]},"indicator_supplement":{"属性":""}}]},{"id":"41","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"2020Q1-Q3白蛋白累计批签发4666.40万瓶","content_offset":["15981","16007"],"indicators":[{"indicator_name":"批签发量","indicator_value":["4666.40万瓶","15998","16007"],"indicator_element":{"时间":["2020Q1-Q3","15981","15990"],"产品":["白蛋白","15990","15993"]},"indicator_supplement":{"属性":""}}]},{"id":"42","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"Q1-Q3国产与进口白蛋白各批签发2221.46万瓶、2444.94万瓶，","content_offset":["16089","16126"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2221.46万瓶","16106","16115"],"indicator_element":{"渠道":["国产","16094","16096"],"时间":["Q1-Q3","16089","16094"],"产品":["白蛋白","16099","16102"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["2444.94万瓶","16116","16125"],"indicator_element":{"渠道":["进口","16097","16099"],"时间":["Q1-Q3","16089","16094"],"产品":["白蛋白","16099","16102"]},"indicator_supplement":{"属性":""}}]},{"id":"43","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"同比增长6.13%、45.70%","content_offset":["16126","16142"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["6.13%","16130","16135"],"indicator_element":{"渠道":["国产","16094","16096"],"时间":["Q1-Q3","16089","16094"],"产品":["白蛋白","16099","16102"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["45.70%","16136","16142"],"indicator_element":{"渠道":["进口","16097","16099"],"时间":["Q1-Q3","16089","16094"],"产品":["白蛋白","16099","16102"]},"indicator_supplement":{"属性":""}}]},{"id":"44","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"2020Q1-Q3静丙累计批签发1055.21万瓶","content_offset":["17405","17430"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1055.21万瓶","17421","17430"],"indicator_element":{"时间":["2020Q1-Q3","17405","17414"],"产品":["静丙","17414","17416"]},"indicator_supplement":{"属性":""}}]},{"id":"45","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"2020Q1-Q3肌丙累计批签发124.89万瓶","content_offset":["18241","18265"],"indicators":[{"indicator_name":"批签发量","indicator_value":["124.89万瓶","18257","18265"],"indicator_element":{"时间":["2020Q1-Q3","18241","18250"],"产品":["肌丙","18250","18252"]},"indicator_supplement":{"属性":""}}]},{"id":"46","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"2020Q1-Q3乙免累计批签发97.77万瓶","content_offset":["18634","18657"],"indicators":[{"indicator_name":"批签发量","indicator_value":["97.77万瓶","18650","18657"],"indicator_element":{"时间":["2020Q1-Q3","18634","18643"],"产品":["乙免","18643","18645"]},"indicator_supplement":{"属性":""}}]},{"id":"47","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"2020Q1-Q3破免累计批签发390.27万瓶","content_offset":["19482","19506"],"indicators":[{"indicator_name":"批签发量","indicator_value":["390.27万瓶","19498","19506"],"indicator_element":{"时间":["2020Q1-Q3","19482","19491"],"产品":["破免","19491","19493"]},"indicator_supplement":{"属性":""}}]},{"id":"48","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"2020Q1-Q3狂免累计批签发842.30万瓶","content_offset":["20284","20308"],"indicators":[{"indicator_name":"批签发量","indicator_value":["842.30万瓶","20300","20308"],"indicator_element":{"时间":["2020Q1-Q3","20284","20293"],"产品":["狂免","20293","20295"]},"indicator_supplement":{"属性":""}}]},{"id":"49","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"2020Q1-Q3八因子累计批签发165.59万瓶","content_offset":["21109","21134"],"indicators":[{"indicator_name":"批签发量","indicator_value":["165.59万瓶","21126","21134"],"indicator_element":{"时间":["2020Q1-Q3","21109","21118"],"产品":["八因子","21118","21121"]},"indicator_supplement":{"属性":""}}]},{"id":"50","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"2020Q1-Q3PCC累计批签发108.84万瓶","content_offset":["21993","22018"],"indicators":[{"indicator_name":"批签发量","indicator_value":["108.84万瓶","22010","22018"],"indicator_element":{"时间":["2020Q1-Q3","21993","22002"],"产品":["PCC","22002","22005"]},"indicator_supplement":{"属性":""}}]},{"id":"51","source_document":"2020Q3血制品批签发数据跟踪：Q3单季度出现下滑，Q1-Q3仍维持增长.pdf","content":"2020Q1-Q3纤维蛋白原累计批签发81.72万瓶","content_offset":["22801","22827"],"indicators":[{"indicator_name":"批签发量","indicator_value":["81.72万瓶","22820","22827"],"indicator_element":{"时间":["2020Q1-Q3","22801","22810"],"产品":["纤维蛋白原","22810","22815"]},"indicator_supplement":{"属性":""}}]}]}